MPS Pharmaa Limited has formally disclosed its Board of Directors' approval for workforce retrenchment as part of its strategic business diversification into natural healthcare products. The company submitted its disclosure under Regulation 30 of SEBI regulations following the Board meeting held on March 03, 2026.

Board Meeting and Regulatory Disclosure

The Board of Directors convened on March 03, 2026, from 04:00 P.M. to 05:45 P.M. at the company's corporate office located at 703, Arunachal Building, 19, Barakhamba Road, Connaught Place, New Delhi. The meeting focused on workforce rationalization aligned with the company's future business plans and operational requirements for manufacturing Ayurvedic, Unani and Homeopathic medicines, drugs and Nutraceutical products.

Workforce Retrenchment Specifications

The company has provided detailed information about the workforce reduction in its regulatory filing. The retrenchment affects factory workers at the manufacturing facility as the company transitions to specialized natural healthcare product manufacturing.

Strategic Business Diversification

The management is planning to commence new business operations in manufacturing Ayurvedic, Unani and Homeopathic medicines, drugs and Nutraceutical products, responding to evolving market trends and increasing consumer demand for natural healthcare solutions. The company had previously communicated its diversification plans through a letter dated September 02, 2025.

The proposed new line of business activities will require a specialized workforce possessing requisite technical qualifications, domain expertise and operational capabilities necessary to establish and manage the renewed business operations.

Legal Compliance Framework

MPS Pharmaa Limited has emphasized strict adherence to regulatory requirements throughout the retrenchment process. The company is conducting the workforce reduction in compliance with applicable provisions of The Industrial Relations Code, 2020 and other relevant labour laws. All statutory dues, compensation and benefits payable to the affected workers are being settled in accordance with applicable regulations.

The company has committed to keeping the Stock Exchange informed of any further material developments related to the proposed business activities as the diversification plan progresses.

MPS Limited has completed its strategic acquisition of Unbound Medicine Inc., USA for $15.18 million, marking a transformative entry into the healthcare knowledge management sector. The acquisition was executed through MPS North America LLC, a wholly-owned subsidiary, and positions the company at the intersection of healthcare and artificial intelligence.

Strategic Healthcare Intelligence Platform

Unbound Medicine operates as a leader in healthcare knowledge management with over 20 years of clinical expertise. The platform serves more than 1,000 healthcare facilities and supports over 5 million clinical lookups annually across 50+ evidence-based databases. The company maintains a robust subscription-based recurring revenue model with 97% customer retention rates.

The platform provides end-to-end healthcare knowledge curation and streamlining, enabling foundational education, just-in-time learning, and informed decision-making for clinicians, educators, and students.

Market Opportunity and Growth Potential

The acquisition targets a market with significant growth drivers, including a projected global healthcare AI and knowledge management market reaching $188 billion by 2030. The AI-driven knowledge management subsector specifically is expected to grow from $3 billion to $102 billion by 2034 at a 42% CAGR.

Unbound's platform addresses critical healthcare challenges, particularly the projected deficit of 10 million health workers by 2033. In the U.S. alone, 57% of physicians cite reducing administrative burden as their top priority, creating substantial demand for intelligent healthcare solutions.

Financial Performance and Margin Expansion Strategy

Unbound currently operates with a 14% EBITDA margin, which MPS plans to systematically improve through operational synergies and shared infrastructure.

The margin expansion strategy focuses on shared services implementation, operational efficiency improvements using MPS tools and technology, and infrastructure optimization including cloud services.

Technology Integration and Competitive Advantages

Unbound differentiates itself through several key technological moats:

• Clinical Authority: Partnerships with marquee institutions like Johns Hopkins for specialized tools like the Hopkins Antibiotic Guide
• Workflow Integration: Seamless API integration into hospital Electronic Health Record (EHR) systems
• AI-Native Architecture: Unified platform spanning reference, education, and test prep with proprietary analytics
• Rapid Authoring: AI-powered delivery of tailored solutions faster than legacy competitors

The platform operates three core solutions: Nursing Central for nursing education, uCentral for medical centers, and Society Solutions for professional medical associations.

Cross-Selling and Geographic Expansion

MPS plans to leverage its global presence to expand Unbound beyond North America into Europe, APAC, and the Middle East. The company expects significant revenue growth through geographic expansion and cross-selling opportunities.

Key expansion strategies include:

• Utilizing MPS's established presence in international markets
• Cross-selling MPS solutions to Unbound's customer base
• Marketing Unbound platform to MPS's existing institutional partnerships
• Leveraging AJE's strong presence in China where 70% of revenue comes from universities and medical institutions

Management and Integration

The acquisition maintains operational continuity with minimal management changes. Founder and CEO Bill Detmer transitions to a strategic advisor role, while the existing management team including CTO, Head of Sales, Head of Marketing, and Head of Product continue in their positions. The management team has been provided with phantom options at the MPS level.

Transaction Details

The final transaction value of $15.18 million reflects post-closing adjustments from the initially disclosed $16.5 million. MPS funded the acquisition through INR 42 crores of debt, which the company considers comfortable given its improved balance sheet and reduced DSO from 60 to 45 days.

Source: None/Company/INE943D01017/cb02d392-0286-4f6f-ae3a-68b7e831c1fd.pdf